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Key Questions  
What is already known about this topic?  
• HS is a chronic, relapsing inflammatory skin condition with potential adverse impacts on health-
related quality of life. 
• The ability to assess HS-specific HRQOL is important to those with HS and to furthering 
research to mitigate the effects of the condition. 
• Development of HS-specific instruments is feasible and existing instruments have limitations.  
What does this study add? 
• This study describes the development, validation, and psychometric properties of the HiSQOL, 
a novel HS-specific HRQOL instrument.  
• HiSQOL is a patient-reported outcome measure developed for clinical trials to address disease-
specific changes in HRQOL. 
 
 
 
  
Abstract  
Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory condition that can have a large 
negative impact on health-related quality of life (HRQOL). A reliable and validated measure of HS-
specific HRQOL in clinical studies is needed. 
 
Objective: To develop and validate the Hidradenitis Suppurtiva Quality Of Life (HiSQOL©) scale, for 
clinical trial measurement of HS-specific HRQOL.  
 
Methods: Stage 1: Qualitative concept elicitation (CE) interviews were conducted with HS patients in 
Denmark (DK) (n = 21) and the United States (US) (n=21). Stage 2: Cognitive debriefing (CD) 
interviews were performed with US HS patients (n = 30) and Danish HS patients (n=30). Stage 3: 
Observational study of 222 HS patients in the US was conducted for item reduction, measure validation 
and assessment of psychometric properties. Stage 4: Observational study of 215 HS patients in 
Denmark was conducted to confirm the psychometric structure derived in stage 3. In both studies - the 
Dermatology Life Quality Index, Hospital Anxiety and Depression Scale, and numerical rating scale for 
pain - were also included.  
 
Results: In CE, 99 items were generated and reduced to 41 after removing duplicates. In CD, 2 items 
were added and 1 items removed. A 42-item instrument was psychometrically assessed. Based on 
psychometric analyses and patient input, the instrument was reduced to 17 items that had strong 
psychometric properties in both US and DK samples.  
 
Discussion: The HiSQOL is a reliable and valid instrument to measure HS-specific HRQOL for clinical 
trials.  
 
  
Introduction 
 
Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory skin condition most commonly 
affecting the groin, axillae, buttocks, and inframammary folds1. Clinical manifestations include inflamed 
nodules, abscesses, tunnels that cause pain, itch, drainage, odor and often eventuate into scars or 
post-inflammatory hyperpigmentation2-4. HS can make activities of daily living, such as walking, sitting, 
and working difficult or impossible. HS lesions and the malodorous drainage can be socially and 
emotionally devastating5,6. Thus, HS has repeatedly been shown to have a large negative impact on 
health-related quality of life (HRQOL) 7-10, severe socio-economic consequences11,12 and even an 
increased risk of suicide13.  
In an effort to the enhance quality and consistency among future treatment studies, a core 
outcome set was recently established for HS14-16. The HIdradenitis Suppurativa cORe outcomes set 
International Collaboration (HISTORIC) reached consensus on a core outcome set that specifically 
recommended assessment of HS-specific HRQOL. HRQOL scales include constructs that are of 
primary concern to the patient and may include the impact of symptoms, functional impairments and 
emotions on HRQOL17,18. Several generic dermatologic HRQOL scales exist, however, generic HRQOL 
measures do not assess the unique and important ways that HS affects patients due to the distinctive 
symptoms and location of the condition9,19,20. Thus, the HS core outcome set established the need for 
an HS-specific HRQOL that included: physical functioning, psychological functioning, psychosocial 
functioning, emotional well-being, and ability to work or study14. There has been a burst of activity to 
address the need for a HS-specific HRQOL instrument and several instruments, as reviewed by 
Chernyshov et al10, have been recently developed. Each instrument has strengths and limitations, such 
as limited evidence of validity and/or reliability or prolonged recall period10,21-27. Also, the focus of the 
core outcome set is to ensure rigorous measurement in interventional clinical trials, so some constructs 
such as scarring, skin damage, or body image may be less amenable to change in the shorter time-
frame of clinical trials. To address the need for a rigorously-developed and psychometrically-sound HS-
specific HRQOL instrument, this group sought to develop and test the Hidradenitis Suppurativa Quality 
of Life (HiSQOL) tool, an instrument designed to measure HS-specific HRQOL of adults with HS in the 
setting of a clinical trial.  
 
 
Methods 
Study design and Participants   
A mixed methods design was utilized and included four phases aligned with guidance from the 
US Food and Drug Administration28. Conduct of the study was overseen by an international group of 
investigators, which included patient research partners, clinicians with expertise in HS, and researchers 
with expertise in instrument development. People with HS who were 18 years or older were identified 
based on diagnostic code for HS (International Classification of Diseases, Ninth Revision (ICD-9) code 
705.83) in the medical record at two academic institutions in the United States (US) and Demark (DK). 
People who gave informed consent, had a confirmed diagnosis of HS, and were fluent in English or 
Danish were recruited by phone and in clinic. This study was approved by the ethics committee of each 
institution and the Danish Data Protection Agency. All participants gave written informed consent prior 
to participation in the study. 
 
Concept Elicitation (CE) 
Semi-structured interviews were conducted with people with HS by two investigators with 
experience (JS, ES). Interviews included open-ended questions with follow-up probing questions 
(Interview guide in Supplement 1). Interviews were audiotaped and transcribed verbatim. Qualitative 
analysis was conducted independently by two researchers in the original language by a native speaker 
with Nvivo 11 software (QSR International, Burlington, MA). Using grounded theory methods29 and 
qualitative analysis software, quotations were assigned a code determined by the underlying concept 
and grouped into higher level concepts. Coding was informed by the model of HRQOL by Ferrans et 
al30 as it was shown to better explain HRQOL31. Conceptual saturation was assessed and achieved.  
Instrument Development 
Items were developed using the qualitative data and the HRQOL model30 by clinicians with 
expertise in HS and four patient research partners were present to ensure the items were relevant and 
comprehensive. Concepts related to active disease were included and concepts clearly related only to 
secondary skin damage, e.g. scarring, were excluded since the anticipated use of the tool is a clinical 
trial setting where changes in active disease but not secondary damage are anticipated. Through 
discussion, the group condensed or eliminated duplicate data. The extant literature guided design of 
the recall period, item stems, response scale, and instructions32. The initial instrument was translated 
into Danish based on recognized methods for cross-cultural adaptation33. Briefly, two bilingual 
translators whose first language was Danish produced two independent translations. One translator 
was aware of the concepts being examined in the instrument, the other was not. An observer 
synthesized a single common form for back-translation, and then two native English speakers without a 
medical background independently translated the form. These forms were consolidated by a committee 
of methodologists, health professionals, and the translators.  
 
 Cognitive Debriefing (CD) / Pilot-testing 
 Interviews and focus groups were conducted to evaluate the relevance of the concepts 
evaluated by the items (content validity), the ability of the target audience (English- or Danish-fluent 
adults with HS) to understand and complete the instrument, completeness, and acceptability (Interview 
guide in Supplement 2). Per CE methods, people with HS were recruited in the US and DK and 
excluded prior CE participants. Participants were asked to complete the instrument using the “think-
aloud” technique, which facilitates feedback on the instrument. The interviewers (JSK, ES) also asked 
probing questions to elicit suggestions. The combined use of these is a rigorous approach to establish 
whether respondents understand the questions in the way the researcher intended34,35. As per CE, 
analysis was conducted with Nvivo 11 software (QSR International, Burlington, MA). 
	
 Field-testing and Psychometric Assessment  
An observational non-interventional non-randomized study was conducted in the US and DK for 
field-testing and further psychometric validation of the HiSQOL candidate items. The field-testing aimed 
for item reduction, examination of dimensionality and definitive selection of items per dimension. Per 
CE, eligibility criteria were applied to identify participants. The HiSQOL instrument, Dermatology Life 
Quality Index (DLQI)
36,37
, the Hospital Anxiety and Depression Scale (HADS)38,39, and numerical rating 
scale (NRS) for pain
40 were administered concurrently.  A web version of all instruments and items was 
developed in REDCap (Research Electronic Data Capture), a secure, web-based application designed 
to support data capture for research studies41. The sample was divided into a development sample for 
item reduction and initial analyses (US sample), and a validation sample (DK sample). HiSQOL and a 
patient-rated perception of change in HS item were administered a second time 24-72 hours later to 
evaluate test-retest reliability. This timeframe was chosen due to the unpredictable, intermittent, and 
rapid onset of HS worsening.  
 
Analysis 
Item response distributions, inter-item correlations, item-total correlations, as well as multiple 
aspects of reliability and validity were evaluated for the candidate instrument using complete 
responses. Confirmatory factor analysis (CFA) and item response theory (IRT), with the graphical log 
linear Rasch model were used to evaluate the items in the long form42,43. Item fit was evaluated by 
dividing the total score into class intervals and plotting observed item means against score intervals 
together with 99% confidence bands. Differential item functioning (DIF) was evaluated using Mantel-
Haentzel test, while local dependence (LD) was evaluated using Yens Q344. When a value was more 
than 0.2 above the average residual correlation it was considered evidence of LD, i.e. when Q3,* was 
larger than 0.2. For all CFA models DIF was added by allowing item thresholds to be different across 
gender or age group and LD was added by including correlated error terms. Unfavorable response 
distributions, inter-item correlation, IRT and CFA data, and DIF or LD results were taken into account in 
the item reduction process, which was overseen by the investigators and three patient research 
partners. We used the US sample as a calibration set to identify a shortened instrument, then did a 
preliminary validation of short form with the US sample. The DK sample was used to confirm the short 
form. 
The sub-scale structure was investigated by comparing a three-dimensional to a bifactor CFA 
model. It was hypothesized that the bifactor model would fit the data better indicating that an overall 
HiSQOL score can be reported alongside domain scores. All CFA models were fitted using M Plus 6th 
edition (Muthen & Muthen, Los Angeles). Fit of the CFA was evaluated based on the Chi-square test of 
model fit, the root mean square error of approximation (RMSEA), the comparative fit index (CFI) and 
the Tucker Lewis Index (TLI). For the RMSEA, a smaller value indicates a closer fit; an RMSEA <.06 is 
considered to reflect good fit, values <.08 are fair, and values above .10 are generally considered to 
reflect poor fit. Values of the CFI and the TLI above .95 are generally accepted as reflecting adequate 
and good fit. 
For convergent validity, it was hypothesized that there would be at least moderate correlation 
between the scores of the HiSQOL instrument and DLQI, HADS, and NRS for pain. This relationship 
was assessed using Spearman’s rank-sum correlations. A correlation of 0–0.09 was considered no 
correlation, 0.1≤0.3 was considered poor, 0.31≤0.6 was considered fair, 0.61≤0.8 was moderate and 
0.81<1 was considered very strong, equal to 1 was considered perfect45. Known groups validity was 
evaluated as the differences in HiSQOL scores among known scoring bands for the DLQI using 
ANOVA46,47. It was hypothesized there would be a significant difference in the mean HiSQOL score 
among the DLQI known score bands. Cronbach’s alpha was used to evaluate internal consistency 
reliability of the instrument. Test-retest reliability was assessed with two instances of complete data in 
the US sample and was assessed using intra-class correlations. Participants who reported stable HS 
were included in this analysis. The standard sample size for convergent validity calculation is a 
minimum of five subjects per item48-50, so a sample size of 225 was estimated based on the 45-item 
scale. This sample size was adequate for test-retest reliability calculations, per guidelines of Bland and 
Altman51, so with 2 repetitions and requiring within-subject standard deviation be within 10% of the 
population value, the minimum sample size was 192.  
 
Results 
Demographic and clinical characteristics of participants in CE and CD stages 
Table 1 details the demographic and clinical characteristics for the CE and CD samples. Race and 
ethnicity information was collected with US participants, but was not collected with Danish participants 
per protocol.  
  
Content elicitation 
Participants most frequently discussed the impact of symptoms as well as psychosocial effects and 
alterations in functions and activities. Examples of patient quotations and the major themes/concepts 
are available in Supplemental Table 3. Saturation was achieved within both country samples. No 
country-level differences in the main concepts or sub-concepts were noted. As a result, a conceptual 
framework was developed and used to generate items to measure the core HRQOL impacts due to HS. 
  
Instrument development  
Based on the CE data and extant literature14,30,52, the investigators generated 99 items. Concepts 
related to active disease were included and concepts clearly related skin damage were excluded since 
the anticipated use of the instrument is a clinical trial setting where changes in active disease but not 
damage are expected. The research team including four patient research partners iteratively discussed 
the item meaning and condensed or eliminated duplicate data, then grouped items with one concept of 
the conceptual model. A 7-day recall period was chosen to capture short-term changes. 32 A 5-point 
item response scale incorporating “extremely,” “very much,” “moderately,” “slightly,” or “not at all” was 
used for all items. The point value assigned to these responses was 4, 3, 2, 1, and 0, respectively. For 
some items, respondents were given the additional option of “Unable to do, due to my HS” and/or “I do 
not normally do this, HS did not influence.” The former option was assigned a score of 4 to indicate the 
severity of the impact of HS, whereas the latter option was assigned a score of 0 to indicate HS did not 
impact it.  
 
Cognitive debriefing / Pilot testing 
Two phases of cognitive debriefing (CD) interviews and focus groups were conducted. The second 
round was conducted to ensure that changes made after the first round were acceptable. Participant 
characteristics are presented in Table 1. Participants indicated that the instrument assessed relevant 
symptoms and impacts. Patients did not identify any missing items. In CD phase 1, instructions and 
items were reorganized or wording simplified. The ‘Concentration Consequences’ section included only 
one item so two items were added to more robustly evaluate this construct. In CD phase 2, minor 
wording changes were made to item responses and no items were added. One item was removed 
because it was felt to represent a global HRQOL question, resulting in a 42-item instrument.  
 
Psychometric Assessment / Field testing 
Table 1 lists the characteristics of the eligible patients included in this stage. Forty-seven 
completed instruments were excluded as the participants did not meet the inclusion criteria. Most 
participants were female, Caucasian, and Hurley stage II; however, there was participation across a 
range of respondents including males, Black, Hispanic, and Hurley stage I and stage III participants.  
Item reduction was conducted with the aim of retaining the most discriminative items and at 
least one item for each concept in the conceptual framework as well the core outcome set. Results of 
analyses along with input from the study team and five people with HS were used to identify a 
shortened 17-item instrument that maintained content coverage with maximum precision. Twenty-eight 
items were deleted due to: floor/ceiling effects, lack of applicability to most people with HS due to 
specificity of the item for a body site, IRT item fit, or DIF with respect to sex. The 17-item HiSQOL 
included four symptom items, eight activity-adaptation items, and five psychosocial items. The item 
scores are summed to create a total ranging from 0 to 68, with higher scores indicating more severe 
impact on HRQOL. The sub-scale scores range from 0 to 16 for symptoms, 0 to 20 for psychosocial, 
and 0 to 32 for activities-adaptations. 
For the symptoms subscale there was evidence of LD for the item pair ‘Pain’ and ‘Itch’ in both 
samples (Q3,*=0.26), while evidence of gender DIF for the item ‘Itch’ was found in the Danish sample 
only. In the multiple groups CFA there was no evidence of DIF, but the item ‘Drainage’ functioned 
differentially across the two samples. For the psychosocial subscale there was evidence of LD for the 
item pair 'Anxious or nervous' and ‘Concentration’ in both samples (Q3,*=0.20) and for the item pair 
'Embarrassed' and ‘Sexual desire’ in the Danish sample only. Regarding DIF there was evidence of 
gender DIF for the item ‘Concentration’ in the US sample only. For the Activities-adaptations subscale 
there was evidence of LD for the item pair ‘Washing yourself’ and ‘Getting dressed’ in both samples 
(Q3,*=0.46) and for the item pair ‘Walking’ and ‘Exercising’ in US sample only. There was evidence of 
gender DIF for the item ‘What you wear’ in the US sample. 
Table 2 shows descriptive statistics, range of inter-item correlations and the item-total 
correlations of the psychometric evaluation using the US sample followed by validation using the 
Danish sample. Structural construct validity was established by CFA that confirmed fit of a bifactor 
model (Chi-Square=633.1, df=342, P<0.0001, RMSEA=0.062 (90% CI 0.055 to 0.070), CFI=0.978, 
TLI=0.976) indicating that the total HiSQOL score or sub-scale scores can be utilized in assessment. 
The bifactor model fitted the data better than a three-dimensional CFA model. The model derived for 
the three subscales for symptoms, psychosocial, and activities-adaptations using multiple groups CFA 
all showed excellent fit to the data (Supplement 4). Further validation using IRT also indicated excellent 
fit of each sub-scale (Supplement 5).  
The internal consistency reliability was excellent with a Cronbach’s alpha of 0.94 for the 
HiSQOL total scale. Each of the three sub-scales also had excellent internal consistency reliability with 
Cronbach’s alpha of 0.81-0.88 (Table 3). Test-retest reliability was also excellent for the HiSQOL total 
scale and each of the three sub-scales (Table 3). The hypotheses related to convergent validity were 
confirmed as the HiSQOL demonstrated very strong correlations between the HiSQOL total score and 
DLQI score (0.90). This is further supported by significant differences in HiSQOL mean score across 
disease severity bands for the DLQI (Figure 1). Additionally, the symptoms and psychosocial subscales 
had moderate convergent validity with the NRS for pain and HADS scores, respectively (Table 3).  
 
Discussion  
Development of an HS-specific HRQOL instrument has identified different aspects of HRQOL 
experienced by adults with HS, some of which are distinct from those captured by existing generic skin 
HRQOL tools such as the DLQI. For example, one of the major themes relates to drainage and odor, 
which are not found in the DLQI. The HiSQOL© is a 17-item HS-specific HRQOL instrument with a 7-
day recall period. Expert HS clinicians and people with HS provided guidance and oversight throughout 
the process to ensure content validity. Items were generated from qualitative research with HS patients 
in two countries to ensure the most important constructs were included using patient-friendly language. 
Item selection took into account the qualitative findings, clinical importance, statistical analyses, and the 
need for the instrument to apply to a variety of participants in clinical trials regardless of age, sex, or 
location of HS disease activity. The final HiSQOL© instrument included items grouped into key sub-
scales, organized around symptom, psychosocial, and functional concepts. It is important to note that 
the HiSQOL© total score and each sub-scale score relating to symptoms, psychosocial, and activities-
adaptations can be used. Importantly, the test–retest reliability was strong and demonstrated stability of 
the HiSQOL© score when disease severity remained unchanged. Of the three instruments used to 
assess convergent criterion validity, the strongest correlation was between HiSQOL© and DLQI (r = 
0.90), which is expected as they assess similar constructs and sample population (adults with skin 
disease). The psychometric assessment of the HiSQOL© also provided evidence on the discriminatory 
ability of the HiSQOL© by demonstrating significant differences in the HiSQOL© score across DLQI 
score bands47.  
The HiSQOL© differs from existing HS-specific HRQOL instruments10. It has 17-items separated 
into 3 sub-scales, that can be used independently or to generate a total score. The Hidradenitis 
Suppurativa Burden Of Disease (HSBOD) is a 19-item instrument with responses on a 10-cm visual 
analog scale53. The HSBOD is divided into two parts with different recall periods: the last 4 weeks (14 
items) and the entire time of having HS (5 items). The HSBOD internal consistency and convergent 
validity were compared against the DLQI with 29 HS patients, but full psychometric evaluation was not 
published. The instrument does not have validated sub-scales. The Hidradenitis Suppurativa Symptom 
Assessment (HSSA)-24 hour and HSSA-7 day are 9-item instruments with a 24-hour or 7-day recall 
period54. The HSSA instruments assess severity of symptoms and signs on an 11-point NRS scale and 
were preliminarily shown to be valid and reliable but a full psychometric evaluation was not published54. 
The Hidradenitis Suppurativa Impact Assessment (HSIA) is a 17-item instrument with a 7-day recall 
period and evaluates impacts of HS, but a full psychometric evaluation is also not published54. Sisic et 
al55 developed an instrument called the Hidradenitis Suppurativa Quality of Life (HS-QoL) measure, 
which has a 6-month recall period and 44 items. Validation was assessed through pilot testing, but full 
psychometric analyses of the instrument structure were not performed56. Thorlacius et al18 also 
performed preliminary work to develop an HS-specific HRQOL measure. Further development of these 
two instruments was curtailed to amalgamate efforts develop the HiSQOL. 
Regarding study limitations, the participants in this study were drawn from referral practices and 
selection or response bias may limit generalizability. The majority of participants were Caucasian, with 
an underrepresentation of people with different races, ethnicities, or cultural beliefs that may influence 
responses to the instrument. However, efforts were made to recruit a broad sample of participants. The 
instrument demonstrates some floor effects and DIF. DIF analyses were only conducted for age and 
sex, so future studies will need to assess for DIF. There are several properties of the HiSQOL that 
remain to be elucidated including the responsiveness, minimal important difference and time to 
complete. While the HiSQOL was developed from patient interviews in two countries, further work is 
needed to confirm cross-cultural validity. Future studies are needed for adolescents, since HS can 
begin with or after puberty57,58.. Although the HiSQOL© was developed for use in clinical trials, future 
studies will evaluate a reduced version of the HiSQOL© (HiSQOL-mini©). In summary, the HiSQOL© 
proved to be acceptable, comprehensible, and has strong evidence for validity and reliability in 
assessing patient-centered outcomes in clinical trials. 
  
 
 
Table 1. Description of samples for concept elicitation, pilot testing, and psychometric assessment 
 
Concept Elicitation  Cognitive Debriefing 1 Cognitive Debriefing 2 
Development 
sample 
Va
sam
 US DK US DK US DK US 
Total participants, n 21 21 15 15 15 15 222 
Age, mean (range) 46.8 (23-74) 
years 
37.9  (19-
63) years 
44.2 (21-
73) years 
37.0 (18-
77) years 
43.9 (25-
68) years 
42.3 (24-77) 
years 
39.6 (range 
19-77) years 
 42.
19-
Sex, n (%) 
       Female 
       Male 
 
16 (76%) 
  5 (24%) 
  
13 (62 %) 
  8 (38 %) 
 
13 (87%) 
  2 (13%) 
  
10 (67 %) 
  5 (33 %) 
 
11 (73%) 
  4 (27%) 
  
11 (73%) 
  4 (27%) 
 
 193 (87%) 
   29 (13%) 
 
 193 
   20 
Race 
      White 
      Black 
      Asian 
      Bi- or Multiracial 
 
14 (67%) 
  3 (14%) 
  1  (5%) 
  3 (14%) 
  
21 (100 %) 
 --  
 -- 
 -- 
 
10 (66%) 
 5 (33%) 
 --  
 -- 
 
NC 
 
  9 (60%) 
  6 (40%) 
  -- 
  -- 
 
NC 
 
  158 (712%) 
    48 (22%) 
      3  (1%)            
    13  (6%) 
 
Ethnicity 
      Hispanic 
      Non-Hispanic 
 
3 (14%) 
19 (86%) 
-- 
-- 
   
 0  (0%) 
15 (100%) 
NC 
   
3 (20%)  
12 (80%) 
NC 
    
     6  (3%) 
 216 (97%) 
Hurley Stage* 
     I, n (%) 
     II, n (%) 
     III, n (%) 
  
        0 
12 (57%) 
  9 (43%) 
  
  3 (14%) 
12 (57%) 
  6 (29%) 
 
         NC 
  
         NC 
 
       NC 
  
       NC 
 
 41  (19%) 
 94  (42%) 
 42  (19%) 
Not reported 
(45, 20%) 
 
  47 
  81 
  32 
Not
(53
US: United States samples, DK: Denmark samples, NC: not collected 
*Hurley stage is a disease severity staging score that categorizes the worst site of HS for a participant based 
on the presence of scarring, fistulas (or tunnels), and confluence of lesions
59
. 
  
 
  
 
 
Table  2. Results of descriptive statistics of items and confirmatory factor analyses of the US and DK samples.  
Development sample (US-based) 
Sub-scale Item Mean SD 
Inter-item 
correlation 
Floor Ceiling 
Item-total 
correlation 
Factor 
Loading 
Symptoms 
 
Pain 2.1 1.3 (0.55 to 0.65) 12.1 17.9 0.70 0.81 
Itch 0.9 1.2 (0.35 to 0.55) 54.3 4.7 0.49 0.55 
Drainage 1.9 1.4 (0.35 to 0.67) 19.6 18.8 0.69 0.90 
Odor 1.7 1.4 (0.36 to 0.67) 26.8 16.7 0.64 0.81 
CFA: Chi-Square=11.1, df=10, p=0.3464. RMSEA=0.023 (90% CI 0.000 to 0.078), CFI=0.999, TLI=0.998. 
Psychosocial 
 
Down or 
depressed 
1.7 1.4 (0.54 to 0.66) 25.3 14.0 0.75 0.90 
Embarrassed 2.3 1.5 (0.40 to 0.66) 18.0 30.1 0.71 0.85 
Anxious or 
nervous 
1.5 1.4 (0.41 to 0.64) 34.5 13.6 0.68 0.80 
Concentration 1.0 1.1 (0.39 to 0.58) 40.7 2.7 0.58 0.65 
Sexual desire 2.2 1.6 (0.39 to 0.58) 24.6 35.2 0.58 0.71 
CFA: Chi-Square=26.9, df=15, P=0.0292. RMSEA=0.059 (90% CI 0.019 to 0.095), CFI=0.991, TLI=0.985. 
 
Activities-
adaptations 
 
Walking 1.2 1.1 (0.32 to 0.63) 35.7 3.1 0.68 0.73 
Exercising 1.8 1.5 (0.39 to 0.63) 27.1 19.0 0.72 0.79 
Sleeping 1.3 1.3 (0.28 to 0.62) 36.0 8.9 0.68 0.80 
Washing 
yourself 
1.4 1.2 (0.38 to 0.68) 29.1 6.2 0.68 0.73 
Getting dressed 1.3 1.3 (0.41 to 0.68) 31.5 5.1 0.72 0.84 
What you wear 2.4 1.3 (0.34 to 0.61) 9.3 26.4 0.62 0.75 
Ability to 
work/study 
1.3 1.4 (0.26 to 0.54) 44.2 14.3 0.60 0.68 
Sexual activity 
difficult 
1.8 1.7 (0.36 to 0.54) 38.0 28.3 0.65 0.76 
Chi-Square=56.9, df=38, P=0.0286, RMSEA=0.046 (90% CI 0.015 to 0.070), CFI=0.992, TLI=0.989. 
Validation sample (DK-based) 
Sub-scales Item Mean SD Inter-item 
correlation 
Floor Ceiling Item-total 
correlation 
Factor 
Loading 
Symptoms 
Pain 2.0 1.3 (0.51 to 0.67) 12.3 14.9 0.72 0.80 
Itch 1.1 1.3 (0.35 to 0.51) 47.4 7.9 0.46 0.55 
Drainage 1.8 1.3 (0.35 to 0.68) 19.9 14.9 0.71 0.91 
Odor 1.6 1.4 (0.35 to 0.68) 28.0 13.6 0.65 0.82 
Chi-Square=8.4, df=8, p=0.3973, RMSEA=0.015 (90% CI 0.000 to 0.083), CFI=1.000, TLI=0.999 
 
 
Psychosocial 
Down or 
depressed 
1.6 1.4 (0.51 to 0.65) 28.3 12.1 0.75 0.89 
Embarrassed 1.9 1.5 (0.43 to 0.62) 25.3 22.3 0.71 0.73 
Anxious or 
nervous 
1.2 1.4 (0.43 to 0.65) 43.9 9.8 0.69 0.90 
Concentration 1.0 1.1 (0.40 to 0.61) 42.2 4.0 0.61 0.87 
Sexual desire 2.1 1.6 (0.40 to 0.57) 25.9 32.8 0.58 0.60 
Chi-Square=27.5, df=15, p=0.0252. RMSEA=0.062 (90% CI 0.022 to 0.099), CFI=0.991, TLI=0.986. 
Activities-
adaptations 
Walking 1.1 1.2 (0.41 to 0.60) 40.3 4.3 0.65 0.77 
Exercising 1.8 1.5 (0.46 to 0.60) 30.2 20.2 0.74 0.85 
Sleeping 1.3 1.3 (0.43 to 0.61) 38.8 9.5 0.69 0.78 
Washing 
yourself 
1.5 1.2 (0.40 to 0.73) 24.1 7.3 0.69 0.82 
Getting dressed 1.4 1.2 (0.40 to 0.73) 29.9 5.6 0.74 0.85 
What you wear 2.3 1.4 (0.39 to 0.54) 11.8 24.8 0.59 0.70 
Ability to 
work/study 
1.1 1.4 (0.39 to 0.52) 52.5 12.5 0.61 0.75 
Sexual activity 
difficult 
1.6 1.7 (0.41 to 0.48) 43.2 24.8 0.57 0.58 
Chi-Square=52.9, df=40, p=0.0829. RMSEA=0.039 (90% CI 0.000 to 0.065), CFI=0.995, TLI=0.994. 
SD: standard deviation 
 
  
 
 
Table 3. Reliability and convergent validity of the HiSQOL Sub-Scales and 
HiSQOL Total Scale 
 Symptom 
sub-scale 
Psychosocial 
sub-scale 
Activities-
Adaptations 
sub-scale 
HiSQOL 
total scale 
Test-retest reliability (ICC) and Internal consistency (α) 
Cronbach’s alpha 
(α)  
0.81 0.85 0.88 0.94 
Test-retest 
correlation (ICC) 
0.85 0.84 0.90 0.90 
Convergent validity 
DLQI   0.87 0.90 
NRS for pain 0.74    
HADS Anxiety  0.69   
HADS 
Depression 
 0.63   
  
  
 
Figure 1. Known groups validity of HiSQOL across established DLQI score groups 
 
  
n (%) 
HiSQOL  p-value*  
Mean SD 
DLQI score bands No effect 22 (5.4%) 3.1 6.2 
<.0001 
Small effect 83 (20.5%) 9.6 6.5 
Moderate effect 101 (24.9%) 19.1 7.6 
Very large effect 116 (28.6%) 32.0 9.5 
Extremely large effect 83 (20.5%) 48.6 8.4 
*p-value for comparison of means across groups 
Based on complete case analysis, n=405 for combined US and DK responses 
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